logo-loader
view4D pharma plc

4D Pharma confirms £7.7mln raised to fund developments and explore partnerships

"This funding will enable us to ensure that we have the best opportunity to build upon the exciting developments announced to date this year"

4D pharma plc -

4D pharma plc (LON:DDDD) confirmed after Monday's close that it had raised gross proceeds of around £7.7mln through a placing and subscription to progress its cancer and coronavirus (COVID-19) developments announced earlier in the day.

The funds were raised through a placing of 16.8mln new shares and a subscription for 5.09mln new shares at a price of 35 each, a 14.6% discount to the firm's closing price on Friday, the last trading day before the fundraising was announced. Directors also subscribed for approximately £510,500 of the shares.

4D said the fundraising will provide sufficient cash to support operations to at least four key clinical study data points over the next eighteen months.

In. statement, Duncan Peyton, 4d Pharma's chief executive commented: "In 2020, 4D pharma has announced multiple key developments which reinforce the company's approach to the development of single strain Live Biotherapeutics.

“These have included the delivery of what we believe to be the first-ever clinical signals of efficacy in the treatment of cancer using LBPs, as well as securing expedited approval to conduct a clinical trial in COVID-19.

“This funding will enable us to ensure that we have the best opportunity to build upon the exciting developments announced to date this year, deliver data from our clinical studies of multiple candidates throughout 2020 and into early 2021, and explore further potential partnerships.”

-- Updates with result of fundraising --

Quick facts: 4D pharma plc

Price: 91 GBX

LSE:DDDD
Market: LSE
Market Cap: £119.57 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of 4D pharma plc named herein, including the promotion by the Company of 4D pharma plc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

4d pharma's Duncan Peyton outlines crucial next stage for its cancer trial

4d pharma plc's (LON:DDDD) Duncan Peyton updates Proactive's Andrew Scott following the news the next stage of its cancer clinical study is underway with four new sites added in the US to accelerate patient recruitment. Up to 30 people per tumour type will participate in Part B of the company’s...

on 7/7/20

2 min read